Westlake Aging Cohort (WeAC)

November 5, 2026 updated by: Westlake University

Westlake Aging Cohort

The Westlake Ageing Cohort (WeAC) is a longitudinal cohort study conducted in Hangzhou, Zhejiang Province, China. The investigators aim to enroll 2,800 participants aged 55 years and older for long-term follow-up. The population will include individuals with neurodegenerative diseases or those at the prodromal stage of cognitive impairment, as well as healthy middle-aged and older adults serving as controls. The investigators will collect their sociodemographic, dietary, lifestyle, clinical, and neuroimaging data, as well as biological samples.

Study Overview

Status

Recruiting

Conditions

Detailed Description

The investigators will recruit middle-aged and aged participants, including healthy controls and individuals with neurodegenerative disorders such as mild cognitive impairment (MCI), Alzheimer's disease (AD), Parkinson's disease dementia (PDD), and dementia with Lewy bodies (DLB), etc. The aim of this study is to construct a longitudinal database that includes sociodemographic, lifestyle, clinical, neuroimaging, and multi-omics data. This database will be used to characterize the molecular signatures of neurodegenerative disorders. In addition, the investigators will identify biomarkers associated with neurodegenerative diseases. Furthermore, the investigators aim to uncover the mechanisms underlying the progression of mild cognitive impairment (MCI) and other neurodegenerative disorders.

Study Type

Observational

Enrollment (Estimated)

2800

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Zhejiang
      • Hangzhou, Zhejiang, China, 310058
        • Recruiting
        • Hangzhou First People's Hospital
        • Contact:
      • Hangzhou, Zhejiang, China, 310058
        • Recruiting
        • Hangzhou Third People's Hospital
        • Contact:
          • Peng Li, Master
        • Contact:
          • Yu Chen, Master

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

55 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All participants must be Chinese residents, regardless of their ethnicity.

Description

Inclusion Criteria:

  1. Age between 55 and 90 years (inclusive) at baseline.
  2. Availability of a companion capable of providing independent functional assessments and fluent in Chinese.
  3. Willingness and ability to regularly complete required surveys and physical examinations as per study protocol.
  4. MMSE scores were required to be 24-30 (inclusive) for healthy controls and MCI; and 20-24 (inclusive) for AD and DLB/PDD patients.
  5. Healthy controls: CDR = 0, memory box = 0. MCI: CDR = 0.5, memory box ≥ 0.5. AD: CDR = 0.5 or 1. The DLB/PDD meets the core features of diagnosis.
  6. Healthy controls exhibit no significant cognitive or functional decline. Patients with MCI have objective cognitive impairment not sufficient for an AD diagnosis. AD patients fulfill the NINCDS-ADRDA criteria. DLB/PDD patients meet their respective international consensus diagnostic criteria. Other neurodegenerative diseases meet the diagnostic criteria.

Exclusion Criteria:

  1. Participants with major medical or neuropsychiatric conditions unrelated to the study purposes were excluded. These included, but were not limited to, psychiatric disorders, cancer, infectious diseases, structural brain abnormalities, and epilepsy.
  2. Current use of psychoactive medications or any other drugs that may affect the study.
  3. Participants with cardiac pacemakers, artificial heart valves, or metallic implants in the eyes, skin, or any other part of the body.
  4. Participants with any other diseases that may affect the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cognitive function
Time Frame: 48 months

Cognitive function will be evaluated using the Mini-Mental State Examination (MMSE, score range: 0-30, with higher scores indicating better cognitive function) and clinical diagnosis provided by physicians.

48 months
Gut microbiome
Time Frame: 48 months

The gut microbiome will be profiled by metagenomic sequencing or ITS rRNA sequencing. In addition, fecal microbiota will be cultured, isolated, and identified.

48 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Brain magnetic resonance imaging
Time Frame: 48 months

Use brain magnetic resonance imaging (MRI) to measure the brain structure and function of participants.

48 months
Positron emission tomography
Time Frame: 48 months

Assess the brain function and neurological disorders by positron emission tomography (PET).

48 months
Brain images relevant inspections
Time Frame: 48 months

Other brain image relevant inspections required for study to measure brain structure and function of participants.

48 months
Electroencephalogram
Time Frame: 48 months

Electroencephalogram (EEG) monitors the electrical activity of the brain. And further measure based on coupled EEG/MEG and eye-tracking.

48 months
Blood biochemical parameters
Time Frame: 48 months

Blood biochemical parameters, including glucose and lipids, will be analyzed using an automated biochemical analyzer.

48 months
Serum inflammatory factors
Time Frame: 48 months

Detect and assess serum inflammatory factors such as IL-1β, IL-6, and IL-12, in serum from participants.

48 months
Health and behavior monitoring
Time Frame: 48 months

Use fitness trackers to record the physiological and behavioral data of participants.

48 months
Sleep data measurement
Time Frame: 48 months

Use the polysomnography (PSG) to record the sleep data of participants to evaluate the sleep quality.

48 months
Continuous glucose monitoring
Time Frame: 48 months

Use the continuous glucose monitoring (CGM) for dynamic blood glucose recording to determine the glycemic control of participants.

48 months
Environmental measurement
Time Frame: 48 months

Use the environmental monitoring device to measure various exposure factors in the participants' living environment.

48 months
Multi-omics data
Time Frame: 48 months

Multi omics results of detecting biological samples such as plasma, peripheral blood mononuclear cells (PBMCs), urine, feces, saliva, etc.

48 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Ju-Sheng Zheng, PhD, Westlake University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 3, 2026

Primary Completion (Estimated)

December 31, 2030

Study Completion (Estimated)

December 31, 2031

Study Registration Dates

First Submitted

December 24, 2025

First Submitted That Met QC Criteria

January 19, 2026

First Posted (Actual)

January 28, 2026

Study Record Updates

Last Update Posted (Actual)

November 6, 2026

Last Update Submitted That Met QC Criteria

November 5, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 20251023ZJS001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.